MedPath

Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE

Not Applicable
Recruiting
Conditions
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Interventions
Device: home-based transcranial direct current stimulation (tDCS)
Registration Number
NCT05791812
Lead Sponsor
University of Regensburg
Brief Summary

It is a one-arm open-label interventional study with transcranial direct current stimulation in an remote home-based setting with the aims to evaluate the feasibility (usability of the device, compliance of patients, usability of the teletherapy), the effectiveness (clinical ratings) and the compatability of this intervention in 20 patients with myalgic encephalomyelitis/chronic fatigue syndrome.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
20
Inclusion Criteria
  • ME/CFS diagnosis according to the Canadian Consensus Criteria
  • residence near Regensburg and mother language German
  • written informed consent
  • stable medication if possible
Read More
Exclusion Criteria
  • contraindications for transcranial direct current stimulation
  • certain neurological conditions as assessed by study physician
  • participation in another study
  • pregnancy and lactation period
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
active treatmenthome-based transcranial direct current stimulation (tDCS)2mA of tDCS for 20 min every weekday for six weeks
Primary Outcome Measures
NameTimeMethod
Usability for the patients6 weeks

Rating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire \[1-7, 26 items, the higher the better\]

Usability for the handlers/clinicians6 weeks

Rating of the usability of the treatment (home treatment and video monitoring) with the user experience questionnaire \[1-7, 26 items, the higher the better\]

Number of days out of 30 the patients used the device6 weeks

Number of days out of 30 the patients used the device

Number of patients who completed the treatment regularly6 weeks

Number of patients who completed the treatment regularly

Effect size for change of fatigue for patients in the per protocol analysis measured with the Chalder Fatigue Scale6 weeks

Effect size for change of fatigue for patients in the per protocol analysis measured with the Chalder Fatigue Scale (fatigue scale; 0-33; the lower the better)

Effect size for change of fatigue for patients in the per protocol analysis measured with the Bell Score6 weeks

Effect size for change of fatigue for patients in the per protocol analysis measured with the Bell Score (fatigue scale; 0-100; the higher the better)

Number of responders according the the clinical global impression change score for patients in the per protocol analysis6 weeks

Number of responders according the the clinical global impression change score for patients in the per protocol analysis (range: 1-7; the lower the better)

Secondary Outcome Measures
NameTimeMethod
Pittsburgh sleep quality index18 weeks

sleep inventory (0-21, the lower the better)

digital span18 weeks

memory test (percentiles; the higher the better)

Major Depression Inventory18 weeks

Depression inventory (0-50, the lower the better)

numeric analogue scale pain18 weeks

pain scale (0-10, the lower the better)

Clinical Global Impression change18 weeks

Clinical Global Impression (1-7, the lower the better)

d2 test18 weeks

concentration test (percentiles; the higher the better)

Bell score18 weeks

fatigue scale (0-100; the higher the better)

World Health Organisation Quality of life scale (abbreviated Version) (WHOQOL-BREF)18 weeks

Quality of life scale inventory (4-20, the higher the better)

Chalder fatigue scale18 weeks

fatigue scale (0-33; the lower the better)

Trial Locations

Locations (1)

Department of Psychiatry and Psychotherapy, University of Regensburg

🇩🇪

Regensburg, Germany

© Copyright 2025. All Rights Reserved by MedPath